More EU competition looms for Plavix
This article was originally published in Scrip
Sanofi-Aventis is facing yet more competition for its blockbuster antithrombotic Plavix (clopidogrel) after the European Medicines Agency gave the green light to several more generic versions.
You may also be interested in...
The bedding-in period is ending for Europe’s one-year-old system for preventing the circulation of fake medicines, and the scheme is gearing up for a more fully operational stage.
EU and US regulators have opposing views when it comes to Merck's applications for a new indication and new dosing schedule for the company's successful PD-1 inhibitor Keytruda.
Regulators have pulled out all the stops in their efforts to get the Ebola vaccine to the marketing authorization stage in Africa.